BeStock  
Stocks › Biotechnology › VKTX

Viking Therapeutics VKTX

US equityMarket cap rank #2398Biotechnology
$24.77 −$1.07 (-4.14%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $25.10 +1.33%
Open$25.62
Prev close$25.84
Day range$24.67 – $26.50
Volume3.65M
Market cap$3.16B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership66.3%-0.08 pts vs. prior quarter
Institutions holding514+1 vs. prior quarter
Insider trades (recent)36 buys / 14 sellsNet buying
Short interest18.95% of floatDays to cover 5.4 · as of 30 Oct 2026
Short-sale volume share16.8%5-day average of daily volume

Short-sale volume as % of daily volume

12%16%20%25%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$18.44M (4 inflow days, 16 outflow days).

Net flow by order size, last 20 sessions

−$9.2MSuper−$9.3MBig−$854.3KMid−$5.6MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 24.8% of shares outstanding.

Largest holders

  • FMR7.69%
  • BlackRock4.83%
  • State Street Global Advisors4.35%
  • Vanguard Capital Management, LLC4.23%
  • Vanguard Portfolio Management, LLC3.70%
  • Two Sigma Investments, LP3.09%
  • Morgan Stanley2.81%
  • Morgan Stanley Investment Management Inc.2.81%

By investor type

  • Mutual Fund45.67%
  • Hedge Fund11.11%
  • Public Company5.65%
  • Private Company2.83%
  • Individual/Insider2.25%
  • Government Pension Fund0.45%
  • Family Office/Trust0.21%
  • VC/PE Fund0.15%

Reported short interest has fallen from 19.10% to 18.95% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
FMR Mutual Fund 2026/Q3 +3,512,449 7.7%
Barclays PLC Public Company 2026/Q3 +548,183 0.5%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +340,509 4.2%
BNY Mellon Advisors, Inc. Mutual Fund 2026/Q3 +299,380 0.3%
Barclays Bank Plc Private Company 2026/Q3 +271,522 0.2%
Vanguard Portfolio Management, LLC Mutual Fund 2026/Q3 +233,650 3.7%
ACT Capital Management Hedge Fund 2026/Q3 +220,200 0.3%
Principal Global Investors, LLC Mutual Fund 2026/Q3 +176,278 0.5%
Quinn Opportunity Partners LLC Hedge Fund 2026/Q3 +171,000 0.1%
BW Gestao de Investimentos Ltda. Family Office/Trust 2026/Q3 +150,000 0.1%
UBS Asset Management Mutual Fund 2026/Q3 +131,264 1.0%
Nuveen Asset Management LLC Insurance Company 2026/Q3 +129,473 0.1%
State Street Global Advisors Mutual Fund 2026/Q3 +1,210,837 4.8%
Leap Investments LP Mutual Fund 2026/Q3 +579,800 0.5%
Columbia Management Investment Advisers, LLC Mutual Fund 2026/Q3 +477,338 1.7%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
31 Jul 2026 Dorothy Gemmell Director Other Acquisition +6,333 – 6,333
31 Jul 2026 Dorothy Gemmell Director Other Derivative Acquisition +40,800 $31.74 40,800
28 Jul 2026 Gregory Zante Chief Financial Officer Open Market Disposition -21,217 $33.47 118,182
28 Jul 2026 Brian Lian Chief Executive Officer Open Market Disposition -148,517 $33.32 2,215,508
28 Jul 2026 Marianne Mancini Former Chief Operating Officer Open Market Disposition -18,217 $33.47 314,293
27 Jul 2026 Gregory Zante Chief Financial Officer Other Acquisition +31,667 – 118,182
27 Jul 2026 Brian Lian Chief Executive Officer Other Acquisition +221,667 – 2,215,508
27 Jul 2026 Marianne Mancini Former Chief Operating Officer Other Acquisition +31,667 – 314,293
31 May 2026 Hubert Chen Chief Medical Officer Other Derivative Acquisition +190,000 $31.27 190,000
9 Mar 2026 Neil Aubuchon Former Chief Commercial Officer Open Market Acquisition +4,475 $33.50 4,475
11 Jan 2026 Neil Aubuchon Former Chief Commercial Officer Other Derivative Acquisition +180,000 $31.76 180,000
4 Jan 2026 Gregory Zante Chief Financial Officer Other Acquisition +41,000 – 94,022
4 Jan 2026 Gregory Zante Chief Financial Officer Open Market Disposition -57,661 $34.24 95,869
4 Jan 2026 Brian Lian Chief Executive Officer Other Acquisition +78,400 – 356,933
4 Jan 2026 Brian Lian Chief Executive Officer Open Market Disposition -233,409 $35.07 2,142,358
4 Jan 2026 Marianne Mancini Former Chief Operating Officer Other Acquisition +41,000 – 94,022
4 Jan 2026 Marianne Mancini Former Chief Operating Officer Open Market Disposition -57,661 $35.07 315,168
1 Jan 2026 Matthew Foehr Independent Director Other Acquisition +3,150 – 3,150
1 Jan 2026 Matthew Foehr Independent Director Derivative Exercise and Sale -16,000 $35.11 132,036
1 Jan 2026 Matthew Foehr Independent Director Other Derivative Acquisition +20,400 $35.42 20,400

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 24,163,022 18.9% 5.4
15 Oct 2026 25,538,849 20.1% 4.4
30 Sep 2026 25,921,759 22.2% 2.2
15 Sep 2026 22,583,758 19.4% 12.3
31 Aug 2026 22,186,520 19.0% 12.4
14 Aug 2026 22,285,459 19.1% 13.3

Discussion

No comments yet — be the first to weigh in on VKTX.

Sign in to join the discussion.

Scroll to Top